WCA
VRTX icon

Westover Capital Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Westover Capital Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-2,594
Closed -$208K – 72
2013
Q2 		$208K Buy
+2,594
New +$191K 0.2% 69

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Westover Capital Advisors's VRTX Position: Q3 2013 in Review

Westover Capital Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q3 2013, closing a stake of 2,594 shares — an estimated $208K sold.

Westover Capital Advisors first reported a position in VRTX in Q2 2013 and held it in 1 quarter. The position peaked at $208K in Q2 2013. 403 funds tracked by Wall St. Rank hold VRTX as of Q3 2013.

  • Westover Capital Advisors reported no remaining Vertex Pharmaceuticals position as of Q3 2013 after selling out during the quarter.
  • Westover Capital Advisors sold 2,594 Vertex Pharmaceuticals shares in Q3 2013, an estimated $208K.
  • Westover Capital Advisors first reported a position in Vertex Pharmaceuticals in Q2 2013 and held it in 1 quarter.
  • Westover Capital Advisors's Vertex Pharmaceuticals position peaked at $208K in Q2 2013.
  • 403 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2013.

Based on Westover Capital Advisors's 13F filing for Q3 2013, filed 12 Nov 2013.